PTSD Trial, Recruiting NCT06111976 Sponsor: Assistance Publique - Hôpitaux de Paris Condition: PTSD
Back to Ptsd

PTSD Trial, Recruiting

NCT06111976
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 18 and 65 years
  • People who have been diagnosed with PTSD (Post-Traumatic Stress Disorder) according to standard medical diagnostic guidelines (DSM-5)
  • People whose PTSD symptoms remain significant (as measured by a score above 40 on a standard PTSD symptom checklist called the PCL-5) after at least 6 weeks of treatment with an approved antidepressant for PTSD — either paroxetine or sertraline
  • People who have health insurance coverage (a specific type of state medical aid called AME is excluded — confirm with trial site)
  • People who have signed a written consent form agreeing to take part

Who may not be able to join:

  • People with a history of epilepsy or seizures
  • People who have a cochlear implant (a type of hearing device implanted in the ear)
  • People who have a cardiac pacemaker, intracardiac lines, or any metal implants in the body
  • People who have previously had rTMS (repetitive brain stimulation therapy), electroconvulsive therapy (ECT), or transcranial direct current stimulation (tDCS)
  • People who are currently receiving a specific type of therapy for PTSD called cognitive-behavioral therapy (CBT)
  • People who have ever been diagnosed with a psychotic disorder, bipolar disorder, antisocial personality disorder, or borderline personality disorder
  • People who have a documented brain injury, including conditions such as dementia, stroke, mini-stroke (transient ischemic attack), head trauma, or brain shrinkage shown on a medical report
  • People who are currently dependent on substances such as alcohol or other drugs (tobacco is not included in this exclusion)
  • People who are currently experiencing acute suicidal thoughts
  • People who do not have sufficient ability to understand and communicate in French, or who are unable to give informed consent
  • People who are pregnant (confirmed by a urine test), breastfeeding, or not using contraception
  • People who are under a legal protection order or who are not free to make their own decisions
  • People who are currently taking part in another clinical trial, or who are within an exclusion period following another clinical trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Florian FERRERI, MD, ph, Assistance Publique - Hôpitaux de Paris

Phone: +33149282635

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
7 March 2024
Est. completion
7 July 2026

Where this trial is recruiting

🇫🇷 France

Primary endpoints

PTSD severity score measured at M1 after 12 sessions of rTMS or sham rTMS and simultaneous reactivation of traumatic memory

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov